Lynn D. Kramer

Eisai (United States) — United States

Medicine · Health Sciences

26h-index18.7kcitations93works8.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(41), Dementia and Cognitive Impairment Research(25), Epilepsy research and treatment(12), Health Systems, Economic Evaluations, Quality of Life(12), Pharmacological Effects and Toxicity Studies(12)

Publications91 total

The Lecanemab Clarity AD Open‐Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48‐Month Analysis
Alzheimer s & Dementia·2025· 1 citedOpen Access
Subcutaneous Lecanemab: Potential Benefits and Place in Therapy
Alzheimer s & Dementia·2025Open Access
Lecanemab Subcutaneous Formulation for Maintenance Dosing in Early Alzheimer’s Disease (AD)
Alzheimer s & Dementia·2025Open Access
Results from a Human Factor Study Supporting Safe and Effective Use of the Lecanemab Subcutaneous Autoinjector
Alzheimer s & Dementia·2025Open Access
Development of Subcutaneous Lecanemab: Establishing the Comparability of Subcutaneous and Intravenous Lecanemab Formulations
Alzheimer s & Dementia·2025Open Access
Target Engagement of Lecanemab on CSF Aβ Protofibril Toxic Species in Clarity AD
Alzheimer s & Dementia·2025Open Access
Clinical and Pharmacologic Profile of a Subcutaneous Lecanemab Formulation
Alzheimer s & Dementia·2025Open Access
Long‐term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open‐label extension study
Alzheimer s & Dementia·2025· 2 citedOpen Access
Baseline predictions of PACC progression trajectories in preclinical AD improve the precision and power of treatment effect assessments
Alzheimer s & Dementia·2025Open Access
Combining CSF MTBR‐tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease
Alzheimer s & Dementia·2025· 1 citedOpen Access
Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease
Alzheimer s & Dementia·2025· 3 citedOpen Access
Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database
Alzheimer s Research & Therapy·2025· 1 citedOpen Access
The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease (P1-3.003)
Neurology·2025· 2 cited
Lecanemab Maintenance Dosing in Early Alzheimer’s Disease: Support for Continued Dosing from Clinical, Pharmacology, and Modeling Data (S23.007)
Neurology·2025· 2 cited
Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency
Alzheimer s & Dementia·2025· 2 citedOpen Access
How Does the Latest Clinical Pharmacology Data & Modeling Support Continued Lecanemab Dosing?
Alzheimer s & Dementia·2024· 1 citedOpen Access
Does the Current Evidence for Lecanemab Mechanism Support a Rationale for Continued Lecanemab Dosing?
Alzheimer s & Dementia·2024· 1 citedOpen Access
Is there Evidence for a Continued Benefit for Long‐Term Lecanemab Treatment? A Benefit/Risk Update from Long‐Term Efficacy, Safety and Biomarker Data
Alzheimer s & Dementia·2024· 7 citedOpen Access
Prediction of regional brain tau levels in early Alzheimer’s disease using plasma pTau217
Alzheimer s & Dementia·2024Open Access
Lecanemab Slows Amyloid‐Induced Tau Pathology as Supported by CSF MTBR‐tau243 in Clarity AD
Alzheimer s & Dementia·2024· 4 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Shobha Dhadda(24), Michael C. Irizarry(20), Chad J. Swanson(14), Michio Kanekiyo(11), Larisa Reyderman(10), June Kaplow(7), Akihiko Koyama(7), Robert Lai(6), Martin Rabe(6), Robert J. Gordon(6), Harald Hampel(6), Reisa A. Sperling(6), George E. Locke(5), Michelle Gee(4), Lars Lannfelt(4), Heather Bradley(4), Donald A. Berry(4), Scott Berry(4), Gordon Pledger(4), David Li(4)